Bright Minds Biosciences Inc (DRUG) Stock Price, Quote & News

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indicatio...

Industry: Biotechnology

Sector: Healthcare

Phone: 647 865 8622

Website: brightmindsbio.com

Address:

19 Vestry Street, New York, United States

Doozio Oct. 4 at 7:56 PM

$MAMA 👀 the $DRUG zzzzz are 3wt. N they said it get $LGND ary out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

Ccperk Oct. 4 at 2:43 PM

$ANRO only sold 10% yesterday which I’ll buy back in if it goes down. Wondering (hoping) if a short squeeze will happen next week like $DRUG did a year ago. Off exchange short volume ratio is 54% and represents 18 million shares. Seems like these big institutions are shorting. Going to be a battle, we will see

0 · Reply

Advance33 Oct. 4 at 11:02 AM

$DFLI $DRUG

0 · Reply

Zbrazeau Oct. 4 at 3:33 AM

$IXHL this is the best thing since $DRUG imo…I believe we see a 50x skyrocket in share price in two weeks.

4 · Reply

BioResearcher Oct. 3 at 7:14 PM

$NEUP $DRUG $SAVA $AVXL Their MK-1167 to treat Alzheimer’s disease has been progressing because Merck found that it works. That drug alone can make this company worth $1 billion potentially. Merck cooperation is a stamp of confidence in their drug.

0 · Reply

BioResearcher Oct. 3 at 6:46 PM

$NEUP This stock is moving similar to $DRUG when it is first discovered by investors. A well-hidden gem with very impressive pipeline of drugs for brain diseases:

1 · Reply

Advance33 Oct. 3 at 5:19 AM

$DFLI is it the new $DRUG ? What Do you think ?

0 · Reply

NVDAMillionaire Oct. 2 at 10:06 AM

$DRUG Really good write-up that perfectly summarizes DRUG's present situation. So if you want to bring your DRUG knowledge up to date or just discover DRUG, this is required reading. https://beyondspx.com/quote/DRUG/analysis/bright-minds-biosciences-high-stakes-innovation-in-cns-disorders-nasdaq-drug

0 · Reply

Nwagn Oct. 1 at 8:38 PM

$DRUG

0 · Reply

OTC85 Sep. 30 at 7:52 PM

$DRCT $NUKK $BREA $CWD $DRUG

0 · Reply

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 7, 2025, 4:45 PM EDT - 5 months ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Apr 16, 2025, 12:09 PM EDT - 6 months ago

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Jan 26, 2025, 6:32 AM EST - 8 months ago

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Jan 7, 2025, 6:50 AM EST - 9 months ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Nov 4, 2024, 2:41 PM EST - 11 months ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Oct 30, 2024, 1:07 AM EDT - 1 year ago

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 18, 2024, 6:50 AM EDT - 1 year ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 16, 2024, 10:45 AM EDT - 1 year ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 15, 2024, 9:09 PM EDT - 1 year ago

Bright Minds is Unaware of Any Material Changes

Oct 3, 2024, 9:00 AM EDT - 1 year ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Aug 8, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 12, 2023, 10:33 AM EDT - 2 years ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 11, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Effective Date of Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Proposed Share Consolidation

Apr 19, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 10, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Feb 27, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 17, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 8, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Jan 27, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 9, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Dec 2, 2022, 7:07 PM EST - 3 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 23, 2022, 11:35 AM EST - 3 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Sep 7, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Aug 31, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 30, 2022, 3:35 PM EDT - 3 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 23, 2022, 9:07 PM EDT - 3 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 3 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Aug 18, 2022, 3:34 PM EDT - 3 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Jun 27, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

May 12, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 2, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Nov 30, 2021, 7:30 AM EST - 4 years ago

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Nov 4, 2021, 8:52 AM EDT - 4 years ago

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Nov 3, 2021, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Doozio Oct. 4 at 7:56 PM

$MAMA 👀 the $DRUG zzzzz are 3wt. N they said it get $LGND ary out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

Ccperk Oct. 4 at 2:43 PM

0 · Reply

Advance33 Oct. 4 at 11:02 AM

$DFLI $DRUG

0 · Reply

Zbrazeau Oct. 4 at 3:33 AM

$IXHL this is the best thing since $DRUG imo…I believe we see a 50x skyrocket in share price in two weeks.

4 · Reply

BioResearcher Oct. 3 at 7:14 PM

0 · Reply

BioResearcher Oct. 3 at 6:46 PM

$NEUP This stock is moving similar to $DRUG when it is first discovered by investors. A well-hidden gem with very impressive pipeline of drugs for brain diseases:

1 · Reply

Advance33 Oct. 3 at 5:19 AM

$DFLI is it the new $DRUG ? What Do you think ?

0 · Reply

NVDAMillionaire Oct. 2 at 10:06 AM

0 · Reply

Nwagn Oct. 1 at 8:38 PM

$DRUG

0 · Reply

OTC85 Sep. 30 at 7:52 PM

$DRCT $NUKK $BREA $CWD $DRUG

0 · Reply

OTC85 Sep. 30 at 7:27 PM

$DRCT $NUKK $BREA $CWD $DRUG

2 · Reply

Nwagn Sep. 30 at 7:00 PM

$DRUG

0 · Reply

Doozio Sep. 30 at 6:29 PM

How? It’s $ETON all the $DRUG zzzzzz 🐒🍌🧠⏰♾️. Don’t od DAVE still gotta get NUTX!! 2020FIF

0 · Reply

Trader1141 Sep. 30 at 6:08 PM

$DRCT this one is known to run hard… keep eyes open $NUKK $BREA $CWD $DRUG

0 · Reply

contra7 Sep. 30 at 4:09 PM

$SBFM $DRUG DRUG revenue is 0 Market Cap is 420 million Stock Price: $60 SBFM revenue is 35 million (2024) Market Cap is 6.65 million Stock Price $1.47 (UNDERVALUED)

1 · Reply

Nwagn Sep. 30 at 2:22 AM

$DRUG hoping we wake up to 60

0 · Reply

Doyapart Sep. 29 at 10:58 PM

$DRUG

0 · Reply

stockanalyzer777 Sep. 29 at 10:44 PM

$SBFM $SBFM has been silent for 3 months. I pray the next PR causes an influx of buying pressure where the stock price settles no less than $70.00 per share. Let $SBFM BE THE NEXT $NUKK , $DRUG or other stocks that ran 8000 %. Hopefully October is our month.

3 · Reply

Chokky Sep. 29 at 9:29 PM

$DRUG 🙏🙏

0 · Reply

Chokky Sep. 29 at 9:29 PM

$DRUG 🔥🔥

0 · Reply

Chokky Sep. 29 at 9:29 PM

$DRUG 💎

0 · Reply

Nwagn Sep. 29 at 6:48 PM

$DRUG doing great

0 · Reply

Market Cap	394.46M
Revenue (ttm)	0.00
Net Income (ttm)	-2.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	99,700
Avg Vol	76,684
Day's Range	N/A - N/A
Shares Out	7.04M
Stochastic %K	34%
Beta	-6.17
Analysts	Strong Sell
Price Target	$81.00